Cutaneous vasculitis with renal impairment complicating interferon-beta 1a therapy for multiple sclerosis;Vascularite cutanée avec atteinte rénale compliquant un traitement par interféron bêta-1a pour une sclérose en plaques

Revue Neurologique

Volumn 160, Issue 11, 2004, Pages 1081-1084

  Zoguéreh, D Débat ^a,e   Boucraut, J ^b   Beau Salinas, F ^c   Bodiguel, E ^a   Lechapois, D ^d   Pomet, E ^a  

^a HÔPITAL DU BOCAGE   (France)

^b Centre d'lmmunologie de Marseille Luminy   (France)

^c Service de Pharmacologie Clinique   (France)

^d centre hospitalier Jacques C ur   (France)

^e CH de Laon   (France)

Author keywords

Cutaneous vasculitis; Interferon beta 1a; Multiple sclerosis; Nephritic syndrome

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; CASE REPORT; DEMYELINATING DISEASE; DRUG HYPERSENSITIVITY; EDEMA; ERYTHEMA; FEMALE; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; INJECTION SITE; KIDNEY DISEASE; MULTIPLE SCLEROSIS; NEPHRITIS; PROTEINURIA; PURPURA; SKIN BIOPSY; TREATMENT OUTCOME; VASCULITIS;

EID: 9444227660     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(04)71147-9     Document Type: Article

References (19)

1. ALBANI C, ALBANI G. (1997). Grave necrosi durante terapia con beta-1b interferon (β-IFN). Minerva Med, 88: 271-272.
2. ASNIS LA, GASPARI AA. (1995). Cutaneous reactions to recombinant cytokine therapy. Am Acad Dermatol, 33: 393-410.
3. BROWN DL, LOGIN IS, BORISH L, POWERS PL. (2001). An urticarial lg E-mediated reaction to interferon β-1b. Neurology, 56: 1416-1417.
4. COHEN BA, GREENBERGER PA, SAINI S. (1998). Delayed occurrence of a severe cutaneous reaction in a multiple sclerosis patient taking interferon beta-1b. Allergy Asthma Proc, 19: 85-88.
5. CORONA T, LEON C, Otrosky-ZEICHNER L. (1999). Severe anaphylaxis with recombinant interferon beta. Neurology, 52: 425.
6. CORONEOS E, PETRUSEVSKA G, VARGHESE F, TRUONG L D. (1996). Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis, 28: 888-892.
7. DHIB M, BAKHACHE E, POSTEC E et al. (1996). Syndrome néphrotique compliquant un traitement par interféron alpha. Presse Med, 25: 1066-1068.
8. ELGART GW, SHEREMATA W, AHN YS. (1997). Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol, 37: 553-558.
9. GARCIA-F-VILLALTA M, DAUDEN E, SANCHEZ J, FRAGA J, RAMO C, GARCIA-DIEZ A. (2001). Local reactions associated with subcutaneous injections of both beta-interferon 1a et 1b. Acta Derm Venereol, 81: 152.
10. GOTSMAN I, ELHALLEL-DARNITSKI M, FRIEDLANDER Z, HAVIV YS. (2000). Beta-interferon-induced nephrotic syndrome in a patient with multiple sclerosis. Clinical Nephrol, 54: 425-426.
11. LEBRUN C. (2001). Traitements immunomodulateurs dans la sclérose en plaques. Méd Thér, 7: 82-87.
12. LUBETZKI C. (2001). Traitement des formes rémittentes de sclérose en plaques. Rev Neurol (Paris), 157: 996-1000.
13. NOUSARI H C, KIMAYAI-ASADI A, TAUSK F A. (1998). Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet, 325: 1825-1826.
14. RADZIWILL A J, COURVOISIER S. (1999). Severe necrotising cutaneous lesions complicating treatment with interferon beta-1a. J Neurol Neurosurg Psychiatry, 67: 115.
15. REID III TJ, LOMBARDO FA, REDMOND J, HAMMOND SL, COFFEY JA, OZER H. (1992). Digital vasculitis associated with interferon therapy. Am J Med, 92: 702-703.
16. SANGSTER G, KAYE S B, CALMAN KC, TOY JL. (1983). Cutaneous vasculitis associated with interferon. Eur J Clin Oncol, 19: 1647-1649.
17. TASHIRO M, YOKOYAMA K, NAKAYAMA M, YAMADA A, OGURA Y, KAWAGUCHI Y, SAKAI O. (1996). A case of nephrotic syndrome developing during postoperative gamma interferon therapy for renal cell carcinoma. Nephron, 73: 685-688.
18. THE PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON-β-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP. (2001). PRISMS-4: long-term efficacy of interferon- β-1a in relapsing MS. Neurology, 56: 1628-1636.
19. WEISS K S. (1992). Nephrotic range of proteinuria and interferon therapy. Ann Intern Med, 116: 347.